<mets:mets xmlns:mets="http://www.loc.gov/METS/" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.loc.gov/METS/ https://www.loc.gov/standards/mets/mets.xsd" OBJID="oai:wwu.de:cb2f00ab-2cd1-40ae-986a-93e389beddad" LABEL="University of Muenster, Institutional Repository MIAMI"  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
          <mets:metsHdr CREATEDATE="2022-11-09T14:53:46">
            <mets:agent TYPE="OTHER" ROLE="OTHER" OTHERTYPE="SOFTWARE">
              <mets:name>Memory Alpha</mets:name>
            </mets:agent>
          </mets:metsHdr>
          <mets:dmdSec ID="DMD_cb2f00ab-2cd1-40ae-986a-93e389beddad">
            <mets:mdWrap MIMETYPE="text/xml" MDTYPE="MODS">
              <mets:xmlData>
                <mods:mods xmlns:mods="http://www.loc.gov/mods/v3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-7.xsd" version="3.7">
                  <mods:titleInfo type="uniform" lang="eng">
                    <mods:title script="Latn">Dual strategies to correct abnormal ion transports in cystic fibrosis using construct therapy</mods:title>
                  </mods:titleInfo>
                  <mods:name type="personal" valueURI="http://d-nb.info/gnd/1201358175">
                    <mods:namePart type="given">Anna Katharina</mods:namePart>
                    <mods:namePart type="family">Kolonko</mods:namePart>
                    <mods:namePart type="date">1991-</mods:namePart>
                    <mods:displayForm>Kolonko, Anna Katharina</mods:displayForm>
                    <mods:role>
                      <mods:roleTerm type="code" authority="marcrelator">aut</mods:roleTerm>
                    </mods:role>
                  </mods:name>
                  <mods:name type="personal" valueURI="http://d-nb.info/gnd/112167985">
                    <mods:namePart type="given">Wolf-Michael</mods:namePart>
                    <mods:namePart type="family">Weber</mods:namePart>
                    <mods:displayForm>Weber, Wolf-Michael</mods:displayForm>
                    <mods:affiliation>FB 13: Biologie</mods:affiliation>
                    <mods:role>
                      <mods:roleTerm type="code" authority="marcrelator">ths</mods:roleTerm>
                    </mods:role>
                  </mods:name>
                  <mods:name type="corporate" valueURI="http://d-nb.info/gnd/5091030-9" altRepGroup="2">
                    <mods:namePart>Universitäts- und Landesbibliothek Münster</mods:namePart>
                    <mods:role>
                      <mods:roleTerm type="code" authority="marcrelator">own</mods:roleTerm>
                    </mods:role>
                  </mods:name>
                  <mods:name type="corporate" valueURI="http://d-nb.info/gnd/5091030-9" altRepGroup="2">
                    <mods:namePart>ULB Münster</mods:namePart>
                    <mods:role>
                      <mods:roleTerm type="code" authority="marcrelator">own</mods:roleTerm>
                    </mods:role>
                  </mods:name>
                  <mods:name type="corporate" valueURI="http://d-nb.info/gnd/5091030-9" altRepGroup="2">
                    <mods:namePart>Landesbibliothek Münster / Universitäts- und Landesbibliothek Münster</mods:namePart>
                    <mods:role>
                      <mods:roleTerm type="code" authority="marcrelator">own</mods:roleTerm>
                    </mods:role>
                  </mods:name>
                  <mods:name type="corporate" valueURI="http://d-nb.info/gnd/5091030-9" altRepGroup="2">
                    <mods:namePart>Universität Münster / Universitäts- und Landesbibliothek</mods:namePart>
                    <mods:role>
                      <mods:roleTerm type="code" authority="marcrelator">own</mods:roleTerm>
                    </mods:role>
                  </mods:name>
                  <mods:genre>doctoralThesis</mods:genre>
                  <mods:genre authority="dct">Text</mods:genre>
                  <mods:originInfo>
                    <mods:dateIssued keyDate="yes">2019</mods:dateIssued>
                    <mods:dateOther>2019-11-29</mods:dateOther>
                    <mods:issuance>monographic</mods:issuance>
                  </mods:originInfo>
                  <mods:originInfo>
                    <mods:dateIssued encoding="w3cdtf">2019-12-10</mods:dateIssued>
                    <mods:dateModified encoding="w3cdtf">2019-12-10</mods:dateModified>
                    <mods:edition>[Electronic ed.]</mods:edition>
                  </mods:originInfo>
                  <mods:language>
                    <mods:languageTerm type="code" authority="iso639-2b">eng</mods:languageTerm>
                  </mods:language>
                  <mods:physicalDescription>
                    <mods:form>electronic</mods:form>
                    <mods:reformattingQuality>access</mods:reformattingQuality>
                    <mods:internetMediaType>application/pdf</mods:internetMediaType>
                    <mods:digitalOrigin>born digital</mods:digitalOrigin>
                  </mods:physicalDescription>
                  <mods:abstract lang="ger">Mukoviszidose (CF) wird durch Mutationen im CFTR-Gen (cystic fibrosis transmembrane conductance regulator) verursacht. Das zugrunde liegende Problem der tödlichen Erbkrankheit ist eine unausgewogene Homöostase von Ionen- und Wassertransporten in sekretorischen Epithelien, was zu Problemen in mehreren Organen führt. Dieses Ungleichgewicht wird durch eine gestörte Cl- Sekretion durch CFTR und eine damit verbundene Na+ Hyperabsorption über den epithelialen Natriumkanal hervorgerufen. Das natürliche Polysaccharid Chitosan könnte aufgrund seiner biologischen Abbaubarkeit und geringen Zytotoxizität als geeigneter nicht-viraler Vektor für eine mögliche Gentherapie dienen. Daher wurden vier auf Chitosan basierende Nanosysteme mit mRNA, Antisense-Oligonukleotiden oder Capsaicin entworfen und untersucht. Die in dieser Arbeit vorgestellten Ergebnisse zeigen einen vielversprechenden Ansatz für die Entwicklung einer Strategie gegen beide Proteine zur Behandlung gestörter Ionentransporte bei CF.</mods:abstract>
                  <mods:abstract lang="eng">Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The underlying problem of the lethal genetic disease is an imbalanced homeostasis of ion and water transports in secretory epithelia causing problems in multiple organs. This imbalance is evoked by impaired Cl- secretion through CFTR and associated Na+ hyperabsorption via the epithelial sodium channel. Until today no gene therapy achieved clinical efficacy mostly due to unwanted immune responses towards viral vectors. The natural polysaccharide chitosan might provide remedy as a suitable non-viral vector for gene delivery purposes because of its biodegradability and low cytotoxicity. Hence, four chitosan-based &#13;
nanosystems containing mRNA, antisense oligonucleotides or capsaicin were designed and explored. The results presented in this Thesis demonstrate a promising start for the development of a dual strategy targeting both proteins to treat abnormal ion transports in CF.</mods:abstract>
                  <mods:tableOfContents lang="eng">TABLE OF CONTENTS............................................................................................................................ I&#13;
LIST OF FIGURES .................................................................................................................................... V&#13;
LIST OF TABLES ................................................................................................................................... VII&#13;
ABBREVIATIONS .................................................................................................................................... IX&#13;
1 INTRODUCTION .............................................................................................................................. 1&#13;
1.1 Chitosan .................................................................................................................. 2&#13;
1.2 Nanosystems .......................................................................................................... 4&#13;
1.2.1 Nanocomplexes ................................................................................................................................ 6&#13;
1.2.1.1 mRNA ....................................................................................................................................... 7&#13;
1.2.1.2 Antisense oligonucleotides .................................................................................................... 8&#13;
1.2.2 Nanocapsules .................................................................................................................................... 9&#13;
1.2.2.1 Capsaicin ...............................................................................................................................10&#13;
1.2.3 Characterization of nanosystems ..................................................................................................11&#13;
1.3 Lung and airway epithelium .................................................................................. 13&#13;
1.4 Cystic fibrosis ........................................................................................................ 16&#13;
1.4.1 Cystic fibrosis transmembrane conductance regulator ................................................................19&#13;
1.4.2 Epithelial sodium channel ..............................................................................................................21&#13;
1.4.1 Interaction of CFTR and ENaC ........................................................................................................23&#13;
1.4.2 Treatment of cystic fibrosis lung disease ......................................................................................24&#13;
1.5 Aim ....................................................................................................................... 28&#13;
2 MATERIALS &amp; METHODS ........................................................................................................ 31&#13;
2.1 Materials ............................................................................................................... 31&#13;
2.2 Microbiological methods ...................................................................................... 31&#13;
2.2.1 Plasmid isolation from CopyCutter™ EPI400™ Escherichia coli ....................................................31&#13;
2.2.1.1 Cultivation of CopyCutter™ EPI400™ Escherichia coli .........................................................32&#13;
2.2.1.2 Mini preparation of plasmid DNA ........................................................................................32&#13;
2.2.1.3 Maxi preparation of plasmid DNA .......................................................................................33&#13;
2.3 Molecular biological methods ............................................................................... 33&#13;
2.3.1 Linearization of pSTI-A120/hCFTR-cDNA .......................................................................................33&#13;
2.3.2 DNA gel electrophoresis .................................................................................................................34&#13;
2.3.3 In vitro transcription .......................................................................................................................35&#13;
2.3.4 RNA gel electrophoresis .................................................................................................................37&#13;
2.3.5 RNA isolation from cells .................................................................................................................38&#13;
2.3.6 Reverse transcriptase polymerase chain reaction ........................................................................ 38&#13;
2.3.7 Polymerase chain reaction ............................................................................................................. 39&#13;
2.3.8 Sequencing ...................................................................................................................................... 40&#13;
2.4 Preparation of nanoformulations .......................................................................... 41&#13;
2.4.1 Chitosan .......................................................................................................................................... 41&#13;
2.4.2 Chitosan-mRNA complexes ............................................................................................................ 41&#13;
2.4.3 Chitosan-ASO complexes ............................................................................................................... 42&#13;
2.4.4 Chitosan-mRNA-ASO complexes .................................................................................................... 44&#13;
2.4.5 Chitosan-lecithin oil-core nanocapsules ....................................................................................... 46&#13;
2.5 Characterization of nanoformulations................................................................... 47&#13;
2.5.1 Determination of hydrodynamic diameter and polydispersity index .......................................... 47&#13;
2.5.2 Determination of zeta potential .................................................................................................... 47&#13;
2.5.3 Stability measurements.................................................................................................................. 47&#13;
2.5.4 Gel retardation assay ..................................................................................................................... 48&#13;
2.5.5 Asymmetric flow field-flow fractionation ..................................................................................... 48&#13;
2.5.6 Transmission electron microscopy ................................................................................................ 50&#13;
2.6 Cell culture ............................................................................................................ 50&#13;
2.6.1 CFBE41o- cells ................................................................................................................................. 50&#13;
2.6.2 H441 cells ........................................................................................................................................ 52&#13;
2.6.3 Primary human nasal epithelial cells ............................................................................................. 54&#13;
2.6.3.1 Processing of nasal specimens ............................................................................................. 55&#13;
2.6.3.2 Nasal brushing procedure .................................................................................................... 56&#13;
2.6.3.3 Liquid covered cultured filters ............................................................................................. 56&#13;
2.6.3.4 Submerged culture ............................................................................................................... 57&#13;
2.6.3.5 Expansion Phase ................................................................................................................... 58&#13;
2.6.3.6 Maintenance Phase .............................................................................................................. 58&#13;
2.6.4 Freezing and thawing of cells ......................................................................................................... 59&#13;
2.6.5 MTT assay ....................................................................................................................................... 60&#13;
2.6.6 Mycoplasma test ............................................................................................................................ 60&#13;
2.6.7 Determination of osmolality .......................................................................................................... 61&#13;
2.7 Transfection of cells .............................................................................................. 61&#13;
2.7.1 Transfection with Lipofectamine®2000 ......................................................................................... 61&#13;
2.7.2 Transfection with nanoformulations ............................................................................................. 62&#13;
2.7.3 Transfection efficiency ................................................................................................................... 63&#13;
2.8 Fluorescence optical methods .............................................................................. 65&#13;
2.8.1 Preparation of glass cover slips ..................................................................................................... 65&#13;
2.8.2 Fixation of transfected cells on glass cover slips .......................................................................... 65&#13;
2.9 Protein biochemical methods ............................................................................... 66&#13;
2.9.1 Isolation of protein from cells ........................................................................................................ 66&#13;
2.9.2 BCA assay ........................................................................................................................................ 66&#13;
2.9.3 SDS-PAGE ........................................................................................................................................ 67&#13;
2.9.4 Semi-dry western blot .................................................................................................................... 68&#13;
2.9.5 Enhanced chemiluminescence detection ......................................................................................71&#13;
2.10 Ussing chamber .................................................................................................... 71&#13;
2.10.1 Functional Ussing chamber measurements .............................................................................72&#13;
2.11 Statistical analysis ................................................................................................. 74&#13;
3 RESULTS .......................................................................................................................................... 75&#13;
3.1 Chitosan-mRNA complexes ................................................................................... 75&#13;
3.1.1 Evaluation of wtCFTR-mRNA ..........................................................................................................75&#13;
3.1.2 Experiments with CFBE41o- cells ...................................................................................................76&#13;
3.1.3 Experiments with primary HNE cells ..............................................................................................79&#13;
3.2 Chitosan-ASO complexes ...................................................................................... 83&#13;
3.2.1 Characterization of chitosan-ASO complexes ...............................................................................83&#13;
3.2.2 Stability of chitosan-ASO complexes .............................................................................................91&#13;
3.2.3 Cell culture experiments with chitosan-ASO complexes ..............................................................95&#13;
3.3 Chitosan-mRNA-ASO complexes ......................................................................... 101&#13;
3.3.1 Characterization of chitosan-mRNA-ASO complexes ................................................................ 101&#13;
3.4 Chitosan-lecithin oil-core nanocapsules .............................................................. 106&#13;
3.4.1 Detection of TRPV1 in primary HNE cells ................................................................................... 106&#13;
3.4.2 Effect of capsaicin on primary HNE cells .................................................................................... 108&#13;
3.4.3 Characterization of chitosan-lecithin oil-core nanocapsules .................................................... 111&#13;
3.4.4 Stability of chitosan-lecithin oil-core nanocapsules .................................................................. 119&#13;
3.4.5 Cell culture experiments with chitosan-lecithin oil-core nanocapsules ................................... 121&#13;
4 DISCUSSION ................................................................................................................................ 125&#13;
4.1 Chitosan-mRNA complexes ................................................................................. 127&#13;
4.1.1 wtCFTR-mRNA transfection leads to increased CFTR activity in human respiratory epithelial cells ...................................................................................................................................................... 127&#13;
4.2 Chitosan-ASO complexes .................................................................................... 130&#13;
4.2.1 Salt benefits the formation of chitosan-ASO complexes ........................................................... 130&#13;
4.2.2 Supplemented transfection medium stabilizes complexes but harms human respiratory epithelial cells ............................................................................................................................................. 133&#13;
4.2.3 ASO transfection successfully inhibits ENaC activity in human respiratory epithelial cells ..... 134&#13;
4.3 Chitosan-mRNA-ASO complexes ......................................................................... 136&#13;
4.3.1 Complexation of two nucleic acids by chitosan forms moderately monodisperse nanoparticles . ...................................................................................................................................................... 136&#13;
4.4 Chitosan-lecithin oil-core nanocapsules .............................................................. 138&#13;
4.4.1 Capsaicin might decrease ENaC activity by activation of TRPV1 in primary human nasal epithelial cells ............................................................................................................................................. 138&#13;
4.4.2 Highly monodisperse and positively charged nanocapsules successfully adsorb wtCFTR-mRNA . ...................................................................................................................................................... 140&#13;
4.4.3 Nanocapsules are highly stable in transfection medium but did not transfect primary human nasal epithelial cells ..................................................................................................................................... 142&#13;
4.5 Conclusion and outlook ....................................................................................... 144&#13;
5 REFERENCES ............................................................................................................................... 147&#13;
6 APPENDIX...................................................................................................................................... 171&#13;
6.1 List of chemicals .................................................................................................. 171&#13;
6.2 List of reagents and kits ...................................................................................... 172&#13;
6.3 List of devices ...................................................................................................... 174&#13;
6.4 Primers................................................................................................................ 177&#13;
6.5 Nucleic acid markers ........................................................................................... 179&#13;
6.6 Antibodies ........................................................................................................... 180&#13;
6.7 Protein markers .................................................................................................. 180&#13;
SCIENTIFIC CONTRIBUTIONS ..................................................................................................... 181&#13;
CURRICULUM VITAE ........................................................................................................................ 183&#13;
ACKNOWLEDGEMENTS .................................................................................................................185</mods:tableOfContents>
                  <mods:targetAudience>specialized</mods:targetAudience>
                  <mods:subject>
                    <mods:topic lang="ger">Mukoviszidose; CFTR; ENaC; Chitosan; mRNA; Antisense-Oligonukleotide; Capsaicin</mods:topic>
                  </mods:subject>
                  <mods:subject>
                    <mods:topic lang="eng">Cystic fibrosis; CFTR; ENaC; chitosan; mRNA; antisense oligonucleotides; capsaicin</mods:topic>
                  </mods:subject>
                  <mods:classification authority="ddc">570</mods:classification>
                  <mods:identifier type="urn">urn:nbn:de:hbz:6-02199695381</mods:identifier>
                  <mods:location>
                    <mods:url access="object in context">https://miami.uni-muenster.de/Record/cb2f00ab-2cd1-40ae-986a-93e389beddad</mods:url>
                  </mods:location>
                  <mods:accessCondition type="use and reproduction">
                    <mods:extension>
                      <ma:maWrap xmlns:ma="http://memoryalpha.ulb.uni-muenster.de">
                        <ma:licence>
                          <ma:displayLabel>CC BY 4.0</ma:displayLabel>
                          <ma:targetUrl>http://creativecommons.org/licenses/by/4.0/</ma:targetUrl>
                        </ma:licence>
                      </ma:maWrap>
                    </mods:extension>
                  </mods:accessCondition>
                  <mods:recordInfo>
                    <mods:recordIdentifier>oai:wwu.de:cb2f00ab-2cd1-40ae-986a-93e389beddad</mods:recordIdentifier>
                  </mods:recordInfo>
                </mods:mods>
              </mets:xmlData>
            </mets:mdWrap>
          </mets:dmdSec>
          <mets:amdSec ID="AMD_cb2f00ab-2cd1-40ae-986a-93e389beddad">
            <mets:rightsMD ID="RIGHTSMD_cb2f00ab-2cd1-40ae-986a-93e389beddad">
              <mets:mdWrap MDTYPE="OTHER" MIMETYPE="text/xml" OTHERMDTYPE="DVRIGHTS">
                <mets:xmlData>
                  <dv:rights xmlns:dv="http://dfg-viewer.de/">
                    <dv:owner>Universitäts- und Landesbibliothek Münster</dv:owner>
                  </dv:rights>
                </mets:xmlData>
              </mets:mdWrap>
            </mets:rightsMD>
            <mets:digiprovMD ID="DIGIPROVMD_cb2f00ab-2cd1-40ae-986a-93e389beddad">
              <mets:mdWrap MDTYPE="OTHER" MIMETYPE="text/xml" OTHERMDTYPE="DVLINKS">
                <mets:xmlData>
                  <dv:links xmlns:dv="http://dfg-viewer.de/">
                    <dv:reference>https://miami.uni-muenster.de/Record/cb2f00ab-2cd1-40ae-986a-93e389beddad</dv:reference>
                    <dv:presentation/>
                  </dv:links>
                </mets:xmlData>
              </mets:mdWrap>
            </mets:digiprovMD>
          </mets:amdSec>
          <mets:fileSec>
            <mets:fileGrp USE="DEFAULT">
              <mets:file MIMETYPE="application/pdf" CHECKSUM="94f5385146d2586fbee06172b83ce54cbec3a233b9f4884ae9d710eddd1eaa2a" CREATED="2019-12-10T08:27:41" CHECKSUMTYPE="SHA-256" SIZE="5185783" ID="ID_FIL_diss_kolonko.pdf_DEFAULT">
                <mets:FLocat xlink:href="https://repositorium.uni-muenster.de/document/miami/cb2f00ab-2cd1-40ae-986a-93e389beddad/diss_kolonko.pdf" LOCTYPE="URL"/>
              </mets:file>
            </mets:fileGrp>
            <mets:fileGrp USE="DOWNLOAD">
              <mets:file MIMETYPE="application/pdf" ID="DOWcb2f00ab-2cd1-40ae-986a-93e389beddad">
                <mets:FLocat xlink:href="https://repositorium.uni-muenster.de/transfer/miami/cb2f00ab-2cd1-40ae-986a-93e389beddad" LOCTYPE="URL"/>
              </mets:file>
            </mets:fileGrp>
          </mets:fileSec>
          <mets:structMap TYPE="PHYSICAL">
            <mets:div ID="ID_PHY_cb2f00ab-2cd1-40ae-986a-93e389beddad" TYPE="physSequence">
              <mets:div ID="ID_PHY_diss_kolonko.pdf">
                <mets:fptr FILEID="ID_FIL_diss_kolonko.pdf_DEFAULT"/>
              </mets:div>
            </mets:div>
          </mets:structMap>
          <mets:structMap TYPE="LOGICAL">
            <mets:div ADMID="AMD_cb2f00ab-2cd1-40ae-986a-93e389beddad" DMDID="DMD_cb2f00ab-2cd1-40ae-986a-93e389beddad" ID="ID_LOG_cb2f00ab-2cd1-40ae-986a-93e389beddad" TYPE="Monograph">
              <mets:div ID="ID_LOG_ID_PHY_diss_kolonko.pdf"/>
            </mets:div>
          </mets:structMap>
          <mets:structLink>
            <mets:smLink xlink:from="ID_LOG_cb2f00ab-2cd1-40ae-986a-93e389beddad" xlink:to="ID_PHY_cb2f00ab-2cd1-40ae-986a-93e389beddad"/>
            <mets:smLink xlink:from="ID_LOG_ID_PHY_diss_kolonko.pdf" xlink:to="ID_PHY_diss_kolonko.pdf"/>
          </mets:structLink>
        </mets:mets>